LANDMARK REDUCE LAP-HF II TRIAL DEMONSTRATES CLINICAL BENEFIT ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
TEWKSBURY, Mass., Feb. 1, 2022 /PRNewswire-AsiaNet/ -- REDUCE LAP-HF II study defines treatable HFpEF patient population for atrial shunt therapyCorvia Medical, Inc, a company dedicated to transforming the treatment of heart failure (HF), today announced results from its REDUCE LAP-HF II randomi...
Authors: LATEST ASIANET NEWS RELEASES